|
Indian Pediatr 2013;50: 801-802 |
|
Updated National Guidelines for Pediatric
Tuberculosis in India, 2012: Some Unresolved Issues
|
CM Kumar and AK Patwari
Department of Pediatrics, Hamdard Institute of Medical
Sciences and Research, Jamia Hamdard, New Delhi 110 062, India. Email:
[email protected]
|
With respect to the recently published updated national
guidelines for pediatric tuberculosis in India [1], we feel
that the following issues need to be clarified for the
benefit of practicing pediatricians.
1. Management algorithm (Fig.1a)
describes that sputum positive cases need not undergo a
chest X-ray. While X-ray chest may not be
necessary for diagnosis and initiation of treatment, it
is vital for follow up and determination of duration of
intensive phase treatment.
2. The guideline says that "There is
no role for inaccurate/inconsistent diagnostics like
serology (IgM, IgG, IgA antibodies against MTB
antigens), various in-house or non-validated commercial
PCR tests and BCG test." PCR is a very useful and
promising diagnostic test for tuberculosis [2-4], though
the existing commercial PCRs are non-validated. Since
the PCRs for TB are likely to be validated in near
future, it should have been mentioned separately rather
than clubbing it with serological and BCG tests.
3. Management of childhood
tuberculosis through DOTS centre is programmatically
logical, but if a child has to attend DOTS centre three
days a week, then his/her academic performance,
self-esteem and mainstreaming is likely to be
compromised. Therefore we need to find a practical
solution to address this very important issue. DOTS
providers are not highly skilled workers, hence one of
the viable solutions could be to train school teachers
assigned to ‘medical room’ in most of the schools and
give them the responsibility of DOTS providers after
initial registration at DOTS center. This could
significantly minimize visits to DOTS centre.
4. The guidelines recommend INH
prophylaxis to "All asymptomatic contacts (under 6 years
of age) of a smear positive case, after ruling out
active disease and irrespective of their BCG, TST or
nutritional status." This appears to be an overstatement
which arbitrarily puts the whole family under a cloud
with consequent social stigma and even partial failure
in compliance by those who really need to take it.
Secondly, are we justified to give single drug
chemoprophylaxis with INH which has a resistance rate of
>5% in our community? What would be the overall impact
on INH resistance?
5. INH chemoprophylaxis in all TST
positive cases has been recommended for 6 months. What
is the evidence to support this conclusion? Duration of
immunosuppressant drugs is variable ranging from weeks
to months. So, how can 6 months chemoprophylaxis be
universal?
6. The statement "a child born to
mother who was diagnosed to have TB in pregnancy should
receive prophylaxis for 6 months, provided congenital TB
has been ruled out" has not been supported by clinical
and investigatory approach for of ruling out congenital
tuberculosis. It is of paramount importance to diagnose
a case of congenital TB and treat as a new case as early
as possible as untreated disease is invariably fatal
[5]. Therefore, diagnostic algorithm of congenital TB
must be included in the guidelines both for exclusion as
well as for treatment.
References
1. Kumar A, Gupta D, Sharath BN, Singh V,
Sethi GR, Prasad J. Updated National Guidelines for
Pediatric Tuberculosis in India, 2012. Indian Pediatr. 2013;
50:301-6.
2. Lee HS, Park KU, Park JO, Chang
HE, Song J, Choe G. Rapid, sensitive, and specific detection
of Mycobacterium tuberculosis complex by real-time
PCR on paraffin-embedded human tissues. J Mol Diagn. 2011;13:390-4.
3. Peter JG, van Zyl-Smit RN, Denkinger
CM, Pai M. Diagnosis of TB: State of the art. European
Respiratory Monograph. 2012:58:124-43.
4. Boehme CC, Saacks S, O’Brien RJ. The
changing landscape of diagnostic services for tuberculosis.
Semin Res Crit Care Med. 2013;34:17-31.
5. Cantwell MF, Sehab ZM, Costello AM, et al.
Brief report: congenital tuberculosis. New Engl J Med.
1994;330: 1051-4.
|
|
|
|